EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis

Yajing Wu, Vivek Verma iD, Carl M Gay, Yujia Chen, Fei Liang iD, Qiang Lin, Jianing Wang, Wei Zhang, Zhouguang Hui iD, Min Zhao, Jun Wang, Joe Y Chang iD

Cancer · 2023-07 · 129 (13) · 1969-1985

DOI: 10.1002/cncr.34755 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer, online erschienen am 30.03.2023. Verfasst von Yajing Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuan…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 86 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant immunotherapy (nIT) is a rapidly emerging paradigm for advanced resectable non‐small cell lung cancer (NSCLC). The objectives of this PRISMA/MOOSE/PICOD‐guided systematic review and meta‐analysis were (1) to assess the safety and efficacy of nIT, (2) to compare the safety and efficacy of neoadjuvant chemoimmunotherapy (nCIT) versus chemotherapy alone (nCT), and (3) to explore predictors of pathologic response with nIT and their association with outcomes.

Methods

Eligibility was resectable stage I–III NSCLC and the receipt of programmed death‐1/programmed cell death ligand‐1 (PD‐L1)/cytotoxic T‐lymphocyte–associated antigen‐4 inhibitors before resection; other forms and modalities of neoadjuvant and/or adjuvant therapies were allowed. For statistical analysis, the Mantel–Haenszel fixed‐effect or random‐effect model was used, depending on the heterogeneity (I 2 ).

Results

Sixty‐six articles met the criteria (eight randomized studies, 39 prospective nonrandomized studies, and 19 retrospective studies). The pooled pathologic complete response (pCR) rate was 28.1%. The estimated grade ≥3 toxicity rate was 18.0%. Compared with nCT, nCIT achieved higher rates of pCR (odds ratio [OR], 7.63; 95% confidence interval [CI], 4.49–12.97; p < .001), progression‐free survival (PFS) (hazard ratio [HR] 0.51; 95% CI, 0.38–0.67; p < .001), and overall survival (OS) (HR, 0.51; 95% CI, 0.36–0.74; p = .0003) but yielded similar toxicity rates (OR, 1.01; 95% CI, 0.67–1.52; p = .97). The results remained robust on sensitivity analysis when all retrospective publications were removed. pCR was associated with improved PFS (HR, 0.25; 0.15–0.43; p < .001) and OS (HR, 0.26; 95% CI, 0.10–0.67; p = .005). PD‐L1 expressors (≥1%) were more likely to achieve a pCR (OR, 2.93; 95% CI, 1.22–7.03; p = .02).

Conclusions

In patients with advanced resectable NSCLC, neoadjuvant immunotherapy was safe and efficacious. nCIT improved pathologic response rates and PFS/OS over nCT, particularly in patients who had tumors that expressed PD‐L1, without increasing toxicities. Plain Language Summary This meta‐analysis of 66 studies showed that neoadjuvant immunotherapy for advanced resectable non‐small cell lung cancer is safe and efficacious. Compared with chemotherapy alone, chemoimmunotherapy improved pathologic response rates and survival, particularly for patients who had tumors that expressed programmed cell death ligand‐1, without increasing toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansNeoadjuvant TherapyB7-H1 AntigenLigandsProspective StudiesRetrospective StudiesImmunotherapy

Stichwörter der Autor:innen

immunotherapyneoadjuvantnon-small cell lung cancerpathologic responsesurvival

Substanzen

B7-H1 AntigenLigands

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Head/Neck and Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu, China.
  • Department of VIP Medical Services & Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical, Beijing, China.

ORCID-Profile: Vivek Verma, Fei Liang, Zhouguang Hui, Joe Y Chang

Zitieren

APA

Wu, Y., Verma, V., Gay, C. M., Chen, Y., Liang, F., Lin, Q., Wang, J., Zhang, W., Hui, Z., Zhao, M., Wang, J., & Chang, J. Y. (2023). Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis. Cancer, 129(13), 1969-1985. https://doi.org/10.1002/cncr.34755

Vancouver

Wu Y, Verma V, Gay CM, Chen Y, Liang F, Lin Q, et al. Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis. Cancer. 2023;129(13):1969-1985. doi:10.1002/cncr.34755

BibTeX
@article{Wu2023,
  author = {Wu, Yajing and Verma, Vivek and Gay, Carl M and Chen, Yujia and Liang, Fei and Lin, Qiang and Wang, Jianing and Zhang, Wei and Hui, Zhouguang and Zhao, Min and Wang, Jun and Chang, Joe Y},
  title = {Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis},
  journal = {Cancer},
  year = {2023},
  volume = {129},
  number = {13},
  pages = {1969--1985},
  doi = {10.1002/cncr.34755}
}
Kostenlos starten →